

1 **Title:** Impact of COVID-19 vaccination on symptoms and immune phenotypes in vaccine-naïve
2 individuals with Long COVID

3
4 **Authors:** Connor B Grady^{1,2,*}, Bornali Bhattacharjee^{3,4,*}, Julio Silva^{3,*}, Jillian Jaycox³, Lik Wee
5 Lee⁶, Valter Silva Monteiro³, Mitsuaki Sawano⁷, Daisy Massey⁷, César Caraballo^{7,8}, Jeff R.
6 Gehlhausen³, Alexandra Tabachnikova³, Tianyang Mao³, Carolina Lucas³, Mario A. Peña-
7 Hernandez^{3,4}, Lan Xu³, Tiffany J. Tzeng³, Takehiro Takahashi³, Jeph Herrin⁸, Diana Berrent
8 Güthe⁹, Athena Akrami^{10,11}, Gina Assaf¹¹, Hannah Davis¹¹, Karen Harris⁹, Lisa McCorkell¹¹,
9 Wade L Schulz^{5,7,12}, Daniel Grffin¹³, Hannah Wei¹¹, Aaron M Ring³, Leying Guan^{5,14}, Charles
10 Dela Cruz^{4,5,15}, Akiko Iwasaki^{3,5,16,†}, Harlan M Krumholz^{5,7,17,18,†}

11
12 **Affiliations:**

13 1. Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine,
14 University of Pennsylvania, Philadelphia, Pennsylvania.

15 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston,
16 Massachusetts.

17 3. Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut.

18 4. Department of Microbial Pathogenesis, Yale University School of Medicine, New Haven,
19 Connecticut, USA.

20 5. Center for Infection and Immunity, Yale School of Medicine, New Haven, Connecticut.

21 6. Adaptive Biotechnologies, Seattle, WA, USA.

22 7. Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven,
23 Connecticut.

24 8. Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut.

25 9. Survivor Corps.

26 10. Sainsbury Wellcome Centre, University College London, London, UK.

27 11. Patient-Led Research Collaborative.

28 12. Department of Laboratory Medicine, Yale University School of Medicine, New Haven,
29 Connecticut.

30 13. Department of Medicine, Columbia University Vagelos College of Physicians and Surgeons,
31 New York City, New York.

- 32 14. Department of Biostatistics, Yale School of Public Health, New Haven, Connecticut
33 15. Department of Medicine, Section of Pulmonary and Critical Care Medicine, Yale University
34 School of Medicine, New Haven, Connecticut.
35 16. Howard Hughes Medical Institute, Chevy Chase, Maryland.
36 17. Department of Health Policy and Management, Yale School of Public Health, New Haven,
37 Connecticut.
38 18. Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of
39 Medicine, New Haven, Connecticut.

40
41

42 *: Indicates equal contribution

43 †: Co-senior and corresponding authors

44 Correspondence can be addressed to: akiko.iwasaki@yale.edu and harlan.krumholz@yale.edu

45
46
47
48
49
50
51
52
53
54
55
56
57
58

59 **Abstract**

60 **Background:** Long COVID contributes to the global burden of disease. Proposed root cause
61 hypotheses include the persistence of SARS-CoV-2 viral reservoir, autoimmunity, and reactivation
62 of latent herpesviruses. Patients have reported various changes in Long COVID symptoms after
63 COVID-19 vaccinations, leaving uncertainty about whether vaccine-induced immune responses
64 may alleviate or worsen disease pathology.

65 **Methods**

66 In this prospective study, we evaluated changes in symptoms and immune responses after COVID-
67 19 vaccination in 16 vaccine-naïve individuals with Long COVID. Surveys were administered
68 before vaccination and then at 2, 6, and 12 weeks after receiving the first vaccine dose of the
69 primary series. Simultaneously, SARS-CoV-2-reactive TCR enrichment, SARS-CoV-2-specific
70 antibody responses, antibody responses to other viral and self-antigens, and circulating cytokines
71 were quantified before vaccination and at 6 and 12 weeks after vaccination.

72 **Results**

73 Self-report at 12 weeks post-vaccination indicated 10 out of 16 participants had improved health,
74 3 had no change, 1 had worse health, and 2 reported marginal changes. Significant elevation in
75 SARS-CoV-2-specific TCRs and Spike protein-specific IgG were observed 6 and 12 weeks after
76 vaccination. No changes in reactivities were observed against herpes viruses and self-antigens.
77 Within this dataset, higher baseline sIL-6R was associated with symptom improvement, and the
78 two top features associated with non-improvement were high IFN- β and CNTF, among soluble
79 analytes.

80 **Conclusions**

81 Our study showed that in this small sample, vaccination improved the health or resulted in no
82 change to the health of most participants, though few experienced worsening. Vaccination was
83 associated with increased SARS-CoV-2 Spike protein-specific IgG and T cell expansion in most
84 individuals with Long COVID. Symptom improvement was observed in those with baseline
85 elevated sIL-6R, while elevated interferon and neuropeptide levels were associated with a lack of
86 improvement.

87

88

89

90 **Plain language summary**

91 The impact of the COVID-19 vaccine on vaccine-naïve individuals suffering from Long COVID
92 is uncertain. This study assessed the experience and immune signatures of 16 unvaccinated
93 participants with Long COVID. A total of 10 participants had improved health status after
94 vaccination, and one person reported only worsening health. As expected, vaccination increased
95 immune cells and antibodies against the viral spike protein. Immune signatures may prove to be
96 predictors of health status after vaccination. However, given the small number of participants,
97 these initial findings need further validation.

98

99

100 **Introduction**

101 Long COVID, also known as post-acute sequelae of SARS-CoV-2 infection (PASC), is a
102 debilitating condition following acute SARS-CoV-2 infection.¹⁻⁶ It can significantly impact
103 people's lives, including their ability to return to work and engage in other social activities.^{7,8}
104 Although investigators have launched several prospective clinical trials of Long COVID
105 treatment,⁹⁻¹² no definitive therapies exist.

106 Viral persistence is a possible contributing factor for Long COVID.¹³⁻¹⁵ So far, several
107 reports have suggested the persistence of active SARS-CoV-2 reservoirs in Long COVID
108 patients^{16,17} and that vaccination could assist in clearing persistent virus. However, the impact of
109 vaccination after developing Long COVID remains unclear.¹⁸ In a recent study, Nayyerabadi et al.
110 reported the alleviation of symptoms, an increase in WHO-5 well-being scores, and a decrease in
111 inflammatory cytokines after vaccination among participants with Long COVID.¹⁹

112 At the same time, there are concerns that the vaccine's spike protein or innate immune
113 stimuli induced by the lipid nanoparticles and mRNA may exacerbate Long COVID symptoms by
114 activating immunological pathways.^{14,20} These concerns have contributed to vaccine hesitancy
115 among individuals with Long COVID.²¹ Consequently, it is crucial to investigate the effect of
116 vaccination on Long COVID symptoms.

117 Accordingly, we launched the Yale COVID-19 Recovery Vaccine Study: Measuring
118 Changes in Long Covid Symptoms After Vaccination (NCT04895189), a prospective, unblinded,
119 observational study to evaluate changes in Long COVID symptoms, their prevalence, and burden.
120 Immune responses before and after receiving the COVID-19 vaccine were evaluated to assess
121 vaccine responses and identify factors associated with health outcomes in vaccine-naïve
122 individuals with Long COVID.²² This report presents findings from 16 participants recruited
123 between May 3, 2021, and February 2, 2022.

124

125 **Methods**

126 **Study design**

127 A pre-post, prospective observational study was conducted among unvaccinated individuals
128 experiencing Long COVID symptoms who intended to receive a COVID-19 vaccine as part of the
129 routine clinical care (ClinicalTrials.gov Identifier: NCT04895189). Participants completed a
130 survey before vaccination to collect demographic and acute COVID-19 infection information and

131 their baseline (i.e., pre-vaccination) Long COVID symptom experience (survey included in the
132 **Supplementary file**). Participants were vaccinated with any approved COVID-19 vaccine and
133 then asked to complete three follow-up surveys at 2, 6, and 12 weeks after receiving the first
134 vaccine dose of the primary series. SARS-CoV-2 specific humoral responses, responses to
135 common viral pathogens and autoantigens, T-cell repertoire sequencing, and soluble immune
136 modulators were quantified in a subset of participants before vaccination and at 6 (\bar{x} : 6.6) and 12
137 (\bar{x} : 13.4) weeks after vaccination. This study was approved by the Yale University Institutional
138 Review Board (IRB #2000030423).

139

140 **Patient involvement**

141 Patient advocacy groups were actively engaged in the conception and design of the study.
142 The idea for the study originated from a Survivor Corps poll posted to their Facebook page, many
143 of whom had COVID-19 and suffered from Long COVID. Their poll showed that 40% of
144 respondents with self-reported Long COVID had mild to full symptom resolution after vaccination
145 while 14% reported worsening of their symptoms. In response, hypotheses were developed as to
146 how vaccination might impact Long COVID symptoms.^{23,24} Survivor Corps aided in participant
147 recruitment. The Patient-Led Research Collaborative, a self-organized group of Long COVID
148 patient-researchers working on patient-led research around the Long COVID experience, was
149 enlisted to contribute to the study design. Both groups advocated for including individuals without
150 a positive PCR test for SARS-CoV-2 and helped develop study surveys. Surveys were also
151 informed by prior survey studies.^{7,25–29}

152

153 **Eligibility**

154 Eligible individuals included unvaccinated individuals 12 years or older who self-reported
155 Long COVID (based on the presence of symptoms that started after COVID-19 and persisted more
156 than two months) and planned to receive the COVID-19 vaccine. To verify past COVID-19 illness,
157 individuals must have had a positive COVID-19 test (PCR or antigen) more than two months prior,
158 have had a positive COVID-19 antibody or T-cell test, have been hospitalized for COVID-19, or
159 have been diagnosed by a clinician as having COVID-19. Participants also had to be willing to
160 travel to New Haven, Connecticut to provide blood and saliva samples. Recruitment was

161 conducted through social media advertisements and patient support groups. Participants were not
162 compensated for their involvement.

163

164 **Outcomes**

165 The primary outcome was whether individuals' overall health condition improved, stayed
166 the same, or worsened after receiving a COVID-19 vaccine. Secondary outcomes included changes
167 in symptom prevalence and severity and associated changes in immune response to the COVID-
168 19 vaccine. The immunophenotyping assays included the detection of SARS-CoV-2-specific
169 antibody responses, SARS-CoV-2 specific T cell enrichment, antibody responses to other common
170 viruses and quantitation of soluble immune mediators.

171

172 **Data collection**

173 Before vaccination, demographic, acute COVID-19, and persistent symptom information was
174 collected by survey. Participants were asked to rate their symptoms in terms of how much physical
175 pain or discomfort the symptom caused ("physical effects") and how much each symptom
176 impaired their social or family functioning compared to before infection ("social effects") on a 5-
177 level Likert scale from "not at all" to "very much" (**Supplementary table 1**). We provided a list
178 of 125 symptoms developed through a literature review and prior Long COVID symptoms
179 lists.^{7,8,26} Participants were asked the same questions on the three post-vaccination surveys (2, 6,
180 and 12 weeks after vaccination). Overall health change was measured with the question, "Would
181 you say that your overall health, as compared to your health before the vaccine, is worse, better,
182 or the same?" at 2, 6, and 12 weeks after vaccination. Data collection was performed using RedCap
183 version 12.0.25 (Vanderbilt University). All survey data were self-reported. Blood samples were
184 collected on-site before vaccination and at 6 and 12 weeks after vaccination. Further information
185 on the study's design, eligibility criteria, and data collection are available online.²²

186

187 **Biospecimen processing**

188 Whole blood was collected in sodium-heparin-coated vacutainers (BD 367874, BD
189 Biosciences) and EDTA-coated vacutainers (BD 367856, BD Biosciences). For each participant,
190 unique study identifiers were provided upon collection. Plasma samples were collected after
191 centrifugation of whole blood at 600×g for 10 minutes at room temperature (RT) without brake

192 from sodium-heparin-coated tubes as previously described.³⁰ The blood samples collected in
193 EDTA-coated tubes were frozen and subsequently shipped to Adaptive Biotechnologies for TCR
194 sequencing.

195

196 **Quantitation of SARS-CoV-2 specific antibody levels by ELISA**

197 ELISA assays were performed as previously described.³⁰ Briefly, MaxiSorp plates (96
198 wells; 442404, Thermo Scientific) were coated with recombinant SARS-CoV-2 S1 (S1N-C52H3-
199 100 µg, ACROBiosystems), receptor-binding domain (RBD) (SPD-C52H3- 100 µg,
200 ACROBiosystems) and the nucleocapsid protein (NUN-C5227-100 µg, ACROBiosystems) at a
201 concentration of 2 µg/ml in PBS and were incubated overnight at 4 °C. The primary antibodies
202 used for the standard curves were human anti-spike (SARS-CoV-2 human anti-spike [AM006415;
203 91351, Active Motif]) and human anti-nucleocapsid (SARS-CoV-2 anti-nucleocapsid [1A6; MA5-
204 35941, Active Motif]) and HRP anti-human IgG antibody (1:5,000; A00166, GenScript) was the
205 secondary antibody.

206

207 **TCR sequencing & SARS-CoV-2 Specific TCR assignment**

208 Immunosequencing of the third complementarity determining (CDR3) regions of TCR-β
209 chains was carried out using ImmunoSEQ Assays (Adaptive Biotechnologies). Samples were
210 classified as positive or negative for detection and enrichment of COVID-specific T cells using
211 four of Adaptive's COVID-19 classifiers: V1 classifier, V3 classifier, spike classifier and non-
212 spike classifier. The V1 classifier was trained comparing peripheral repertoires from acute COVID
213 and convalescent subjects with control samples collected pre-pandemic.^{31,32} The V3 classifier was
214 trained on a larger dataset that included subjects with natural infection as well as those that were
215 vaccinated as positive cases. The sequences in the V3 classifier were cross-referenced against data
216 from MIRA (multiplexed antigen-stimulation experiments) experiment to develop two additional
217 classifier.^{32,33} The spike classifier identifies the spike-specific signal while the non-spike classifier
218 (with vaccinated samples included as controls) identifies natural infection using the non-spike
219 signal. T cell responses are categorized as negative, positive, and “No Call” (representing samples
220 with an insufficient number of T cell rearrangements to make a definitive negative call).

221

222 **Rapid Extracellular Antigen Profiling (REAP) Library Expansion**

223 The new yeast library (Exo205) containing 6,452 unique antigens was used. IgG isolations
224 and REAP selections were done as previously described.³⁰ Briefly, participant IgGs were purified
225 from plasma using protein G magnetic beads and yeast-reactive IgGs were initially removed by
226 adsorption to yeast transformed with the pDD003 empty vector. A total of 10⁸ induced Exo205
227 yeast cells were washed with PBE and incubated with 10 µg of purified participant IgGs in
228 duplicate. IgG bound yeast cells were selected by anti-human IgG Fc antibody binding (clone
229 QA19A42, Biolegend) and next generation sequencing (NGS) was carried out to identify epitopes
230 based on the protein display barcode on yeast plasmids. REAP scores were calculated as described
231 previously.³⁰

232

233 **Multiplex proteomic analysis**

234 Frozen patient plasma was shipped to Eve Technologies (Calgary, Alberta, Canada) on dry
235 ice to run 13 multiplex panels: Human Cytokine/Chemokine 71-plex Discovery Assay (HD71),
236 Human Cytokine P3 Assay (HCYP3-07), Human Cytokine Panel 4 Assay (HCYP4-19), Human
237 Complement Panel Assay (HDCMP1), Human Myokine Assay (HMYOMAG-10), Human
238 Neuropeptide Assay (HNPMAG-05), Human Pituitary Assay (HPTP1), Human Adipokine Panel
239 2 Assay (HADK2-03), Human Cardiovascular Disease Panel Assay (HDCVD9), Human CVD2
240 Assay (HCVD2-8), Steroid/Thyroid 6plex Discovery Assay (STTHD) Human Adipokine Assay
241 (HDADK5), and TGF-Beta 3-plex Discovery Assay (TGFβ1-3). Samples were sent in two batches
242 with internal controls in each shipment to assess effectiveness of batch correction as described
243 below.

244 To harmonize data across the two batches, ComBat was used, an empirical Bayes method
245 available through the "sva"³⁴ R package (version 3.4.6), designating the initial batch as the
246 reference and incorporating the following covariates: disease status, sex, age, and hormone
247 conditions. The effectiveness of the ComBat was validated using sample replicates between each
248 batch in a matched pairs analysis. Analytes that exhibited significant differences post-correction
249 were excluded from further analysis.

250

251 **Statistical analysis**

252 We prospectively sought to enroll 50-100 participants to evaluate overall health and
253 symptom changes. However, the study was terminated early due to an inability to reach the target

254 sample size given that few people with Long COVID were vaccine naïve. Our final cohort
255 comprised participants who met eligibility, completed the baseline survey, and were vaccinated at
256 least once.

257 Cohort characteristics were reported as frequencies with proportions or medians with
258 ranges. The overall health condition of participants after vaccination compared to before
259 vaccination was described as the proportion of individuals with each response (i.e., better, worse,
260 the same, don't know) at each post-vaccination time point out of the number of individuals with a
261 submitted survey at that time point.

262 For other symptom-related analyses, participants' Likert scale responses to the physical
263 and social effects associated with each symptom were coded numerically (**Supplementary table**
264 **1**). The proportion of symptoms experienced was calculated at each survey as the number of
265 participants experiencing each symptom (i.e., symptom reported and non-zero response to the
266 physical or social effect scales) out of the participants who completed the given survey.

267 The burden of each participant's symptoms was summarized by summing across their
268 responses to the symptom physical and social effect scales, separately, for each survey. Scores
269 could range from 0 to 500 per survey (i.e., 125 symptoms per survey with a maximum score of 4).
270 Higher values suggest greater symptom burden, and a value of 0 suggests no symptom burden.
271 Changes in these values indicates a change in the number of symptoms experienced, the symptom
272 severity, or both. We report the median, 2nd and 3rd quartiles, and range for each survey and effect
273 (i.e., physical and social). Differences between surveys were not tested. Analyses were performed
274 in R (v 4.2.2; R Foundation for Statistical Computing, Vienna, Austria).³⁵

275 Differences in SARS-CoV-2 specific T-cell responses, anti-SARS-CoV-2 antibody
276 responses measured by ELISA and REAP before and after vaccination were assessed using
277 Wilcoxon matched-pairs signed rank tests. To assess correlation between observed T-cell
278 responses and antibody levels as well as to determine concordance between the two different
279 methods of determining anti-SARS-CoV-2 antibody levels, Spearman rank correlations were
280 calculated. The correlation coefficients between assays were used to measure distances [1-absolute
281 (correlation coefficients)], and hierarchical clustering was conducted using Morpheus.³⁶
282 Participants were classified into outcome groups based on self-reported general health status
283 before and after vaccination. The tests were all two-sided and Bonferroni-corrected P-values less
284 than 0.05 were considered statistically significant.

285 Differences in SARS-CoV-2 T-cell responses, antibody levels, anti-viral antibody levels
286 against common viruses and autoantibody levels among symptom outcome groups were also
287 compared using Kruskal-Wallis tests. Further, to estimate the average differences in expression of
288 each cytokine over the course of vaccination we used linear mixed models via Restricted
289 Maximum Likelihood (REML) regression, estimating the cytokine expression over all three
290 timepoints amongst three symptom outcome groups: those who did not improve or felt worse at
291 weeks 6 and 12 post vaccination (n=3; Same/Worse), those who showed marginal improvement
292 (n=2, Marginal [i.e. Better week 6; then Worse week 12]) and those who reported improvement
293 (n=7, Better). The model incorporated a random effect for each individual as a random intercept,
294 nested within their respective symptom outcome groups. The fixed effects in the model included
295 the symptom outcome and time, along with an interaction term between them to investigate any
296 potential modifying effect of time on the symptom outcome group. The analysis was conducted
297 using the JMP statistical software platform (JMP® Pro 17.0.0).

298 Statistical tests were performed using R (v 4.2.2)³⁵, GraphPad PRISM(v 9.5.1), and JMP
299 statistical software platform (JMP® Pro 17.0.0).

300

301 **Machine Learning**

302 Unsupervised hierarchical clustering was conducted on 162 plasma-derived analytes
303 obtained from the multiplex proteomic assays to assess patterns of expression across the cohort
304 using the JMP platform (JMP® Pro 17.0.0). Data was standardized by factor and clustering was
305 done based on Ward's distance.

306 To further identify predictors of symptom improvement from the 162 plasma-derived
307 analytes, we used Partial Least Squares (PLS) analysis via the Non-linear iterative partial least
308 squares (NIPALS) algorithm with k-fold cross validation (k=5). The analysis was conducted using
309 the JMP statistical software platform (JMP® Pro 17.0.0). All plasma factors and sex were
310 incorporated into the model. Final analysis involved reduction to 4 principal components, which
311 simultaneously minimized the Van der Voet's T-squared statistic (0.00, P=1.00) and the Root
312 Mean PRESS (0.27) accounting for a sizeable portion of the variance in the data (cumulative
313 pseudo-R-squared= 0.98). Post-analysis, the Variable Importance on Projection (VIP) score was
314 generated for each feature and bootstrapped using Bayesian Bootstrapping. Bias-corrected 95%
315 confidence intervals were calculated. Only features with 95% confidence intervals above the

316 threshold cutoff of 0.8, corresponding to the standard threshold for importance,^{37,38} were
317 considered significant.

318

319 **Results**

320 Among 429 individuals screened between May 3, 2021 and February 2, 2022, 22 met
321 inclusion criteria and consented to participate and 16 individuals completed the baseline survey
322 and subsequently received a first dose of a COVID-19 vaccine; 14 completed all four surveys.
323 People not enrolled had already received a vaccine, did not plan to be vaccinated, or were not able
324 to travel to New Haven for biospecimen collection. The median age of the 16 included participants
325 was 54 years (range 21-69), 13 (81%) were female, and 14 (88%) identified as Non-Hispanic
326 White (**Table 1**). Immunophenotyping assays were completed on a subset of 11 out of 16. All
327 participants reported that they tested positive for COVID-19 at least once with most reporting a
328 PCR-based test (n=10, 62%).

329

330 **Pre-vaccination health and symptoms**

331 At baseline, on participants' worst days, 9 (56%) felt they were 50% or less of their health
332 before COVID-19. On participants' best days, 7 (44%) reported feeling 51-75% of their health
333 before COVID-19. The median number of symptoms per participant before vaccination was 23
334 (Q1-Q3, 13.8-27). The most frequently reported symptoms, in order, were brain fog (81%), fatigue
335 (75%), difficulty concentrating (69%), difficulty sleeping (62%), heart palpitations (56%),
336 shortness of breath or difficulty breathing (56%), anxiety (50%), memory problems (50%),
337 dizziness (44%), feeling irritable (44%) (**Figure 1**). Three (19%) participants were previously
338 hospitalized due to COVID-19 and 4 (25%) visited the hospital or were hospitalized for COVID-
339 19 more than 2 weeks after onset of acute disease.

340

341 **Post-vaccination changes in overall health**

342 Eleven of 16 participants (69%) received the Pfizer-BioNTech vaccine (Comirnaty[®]), 3
343 (19%) received the Janssen vaccine as their first dose, and 2 (13%) received the Moderna vaccine
344 (SpikeVax[®]). Nine of 13 participants (69%) recommended to receive a second dose in the primary
345 series reported doing so (i.e., Janssen's vaccine in the primary series was single dose). One

346 participant was hospitalized for chest pain three days after receiving their first vaccine dose and
347 again after their second dose.

348 Two weeks after vaccination, 6 out of 14 participants with completed surveys reported their
349 health was better (43%), 3 (21%) said their health was the same, 1(7%) reported worse health, and
350 4 (29%) were not sure of a change (**Figure 2**). At 6 weeks after vaccination, 11 out of 14 (79%)
351 said their health was better than before vaccination, 2 (14%) reported the same health, and 1 (7%)
352 reported worse health. The participant with worse health 2 weeks after vaccination reported better
353 health at 6 weeks. At 12 weeks, 10 out of 16 (62%) reported better health, while 3 (19%) reported
354 the same health and 3 (19%) reported worse health. Two participants who reported better health at
355 6 weeks reported worse health at 12 weeks, which we classified as marginal improvement in
356 subsequent analyses).

357 The median number of symptoms per participant initially decreased from 23 (Q1-Q3 13.8-
358 27, n=16) before vaccination to 19.5 (Q1-Q3 12-30.3, n=14) 2 weeks after vaccination, further
359 declining to 17.5 (Q1-Q3 12.3-25.5, n=14) and 15.5 (Q1-Q3 12.5-24.5, n=16) at 6 and 12 weeks
360 after vaccination, respectively.

361 Among the ten most common symptoms experienced at baseline, fatigue and brain fog
362 remained common with 12 (75%) and 11 (69%) participants still reporting these symptoms 12
363 weeks after vaccination (**Figure 1**). Fewer participants reported difficulty concentrating or
364 focusing at 12 weeks compared with before vaccination (8 [50%] at 12 weeks vs. 11 [69%] before
365 vaccination). Other symptoms decreased modestly over time. The proportion of participants
366 reporting fatigue (12 [75%]), heart palpitations (9 [56%]), and anxiety (8 [50%]) was the same at
367 12 weeks as before vaccination. The proportion of the ten most common symptoms at each survey
368 are presented in **Supplementary table 2**.

369 Symptom burden appeared to decrease after vaccination on both physical and social effect
370 scales (**Figure 3**). Before vaccination, the median physical effect score for all symptoms was 68.5
371 (Q1-Q3 37.5-84, range 13-138, n=16) and the median social effect score was 36.5 (Q1-Q3 14-
372 51.5, range 1-84, n=16), where higher values represent worse symptom burden. Compared to
373 before vaccination, the median physical effect score decreased to 46.5 (Q1-Q3 21.3-67.3, range 5-
374 128, n=14) at 2 weeks after the first COVID-19 vaccine dose, then 36.5 (Q1-Q3 17.8-52.3, range
375 9-104, n=14) 6 weeks after vaccination, and 38.5 (Q1-Q3 15-49.5, range, 0-80, n=16) 12 weeks
376 after vaccination. At 2 weeks after the first COVID-19 vaccine dose, the median social effect score

377 decreased to 27.5 (Q1-Q3 7.3-34, range 1-80, n=14), then 23 (Q1-Q3 11-36.8, range 2-102, n=14)
378 6 weeks after vaccination, and 19 (Q1-Q3 3.8-27.5, range 0-61, n=16) 12 weeks after vaccination.
379

380 SARS-CoV-2-specific T-cells and antibody responses

381 To characterize the T-cell responses to SARS-CoV-2, sequencing of the CDR3 regions of
382 T-cell receptor- β (TCR- β) chains was carried out. There was a significant increase in spike protein
383 (**Figure 4a**; $P_{\text{adjusted}}=0.012$, V1(**Figure 4b**; $P_{\text{adjusted}}=0.011$) and V3 (**Figure 4c**; $P_{\text{adjusted}}=0.011$)
384 classifier scores at 6 weeks post-vaccination, which was indicative of an increase in SARS-CoV-
385 2 specific T-cell clonal depth and breadth upon vaccination. By contrast and as expected, no
386 significant differences were observed in classifier scores for non-spike protein TCRs with
387 vaccination (**Figure 4d**; pre-vaccination vs 6 weeks: $P_{\text{unadjusted}}=0.65$; pre-vaccination vs 12 weeks:
388 $P_{\text{unadjusted}}>0.99$). There were some individuals who retained high SARS-CoV-2 specific TCR
389 clonality at 12 weeks post-vaccination, however the differences in model scores were not
390 statistically significant in comparison with pre-vaccination. There was a significant decrease in V3
391 classifier score at 12 weeks post-vaccination as compared to 6 weeks ($P_{\text{adjusted}}=0.011$), however
392 this observation was not replicated using the V1 or spike specific classifier scores.

393 Next, SARS-CoV-2 antibody responses were evaluated. A significant increase in anti-S1
394 IgG (**Figure 4e**; pre vs 6 weeks: $P_{\text{adjusted}}=0.003$, pre vs 12 weeks: $P_{\text{adjusted}}=0.003$) and anti-RBD
395 IgG (**Figure 4f**; pre vs 6 weeks: $P_{\text{adjusted}}=0.003$, pre vs 12 weeks: $P_{\text{adjusted}}=0.003$) levels at 6 weeks
396 and 12 weeks post-vaccination was observed without any observed significant rise in anti-N IgG
397 levels (**Figure 4g**; pre vs 6 weeks: $P_{\text{unadjusted}}=0.97$, pre vs 12 weeks: $P_{\text{unadjusted}}=0.37$). The anti-S1
398 and anti-RBD IgG antibody levels peaked at 6 weeks (median anti-S1 IgG: 8.8×10^4 ng/mL; median
399 anti-RBD IgG: 5.0×10^5 ng/mL) with a marginal decrease at 12 weeks (median anti-S1 IgG:
400 5.8×10^4 ng/mL; median anti-RBD IgG: 2.2×10^5 ng/mL). To further validate the humoral responses
401 attributed to vaccination, SARS-CoV-2 spike protein reactivities were assessed using REAP.
402 Participant antibody reactivities against Beta, Delta, Epsilon, and Omicron variant RBD epitopes
403 were independently evaluated. A significant increase in reactivity across all non-Omicron RBD
404 epitopes at 6 weeks post-vaccination (**Supplementary figures 1a-c**) and the Epsilon variant across
405 6- and 12-weeks post-vaccination (**Figure 4h**; pre vs 6 weeks: $P_{\text{adjusted}}=0.011$, pre vs 12 weeks:
406 $P_{\text{adjusted}}=0.023$) was observed.

407

408 **IgG responses to herpesviruses and autoantibodies to the extracellular proteome**

409 Given that latent virus reactivation has been a hypothesis behind Long COVID
410 pathobiology and evidence of recent Epstein-Barr Virus (EBV) reactivation has been
411 reported,^{30,39,40} anti-viral REAP reactivities against two families of common viral pathogens
412 namely, *Coronaviridae* (human SARS-CoV-1 viruses) and *Herpesviridae*, were assessed. Rubella
413 vaccine spike antigen served as internal control as no changes were expected in reactivities with
414 COVID-19 vaccination. As expected, there was a significant increase in REAP scores against
415 SARS-COV-1 RBD upon vaccination at 6 weeks (**Figure 4i**; $P_{\text{adjusted}}=0.05$). This increase was
416 maintained at 12 weeks, despite not being statistically significant after multiple testing correction
417 ($P_{\text{unadjusted}}=0.031$; $P_{\text{adjusted}}=0.09$). Herpesvirus reactivities varied across participants. However, no
418 significant decrease in reactivities was observed post-vaccination among the herpesvirus antigens
419 tested including EBV (**Figure 4i**; **Supplementary table 3**). Additionally, no differences in median
420 reactivities were observed against EBV proteins p23 ($P_{\text{unadjusted}}=0.65$) and gp42 ($P_{\text{unadjusted}}=0.06$)
421 across outcome groups at 6 and 12 weeks post-vaccination (**Figures 4j & 4k**).

422 Next, given prior reports of elevated autoantibodies targeting the exoproteome in severe
423 acute COVID19,⁴¹ we assessed for changes in extracellularly targeted autoantibodies during
424 vaccination (**Supplementary figure 2a**). No difference in the number of autoantibody reactivities
425 at baseline (**Supplementary figure 2b**) or in the mean REAP score delta, representing the change
426 in autoantibody magnitude over time (**Supplementary figure 2c**), between the groups was
427 observed. Overall, autoantibodies were stable over time during vaccination (**Supplementary**
428 **figures 2c-e**), with the mean REAP score delta close to 0 for all groups. These results are in
429 concordance to a previous report focusing on autoantibody dynamics during SARS-CoV2 mRNA
430 vaccination in healthy individuals without Long COVID.⁴²

431

432 **Correlation between SARS-CoV-2 specific TCR and antibody levels**

433 To further evaluate the relation between SARS-CoV-2 specific TCR scores with antibody
434 levels and to assess the concordance among the orthogonal methods of antibody detection,
435 correlation analyses were carried out. Three distinct clusters emerged when distances were
436 calculated based on correlation values among TCR classifier scores and anti-SARS-CoV-2
437 antibody concentration as well as between ELISA and REAP assays at different timepoints. Each
438 cluster indicated that there was a general concordance in antibody levels using orthogonal methods

439 and TCR scores based on Spearman's r (r_s) and unadjusted p-values (**Figure 4I, Supplementary**
440 **tables 4 and 5**). It was also observed that higher numbers of pre-vaccination SARS-CoV-2 specific
441 TCR repertoire resulted in higher titers of antibodies both at pre-vaccination, 6- and 12-weeks
442 post-vaccination along with an increase in spike protein specific TCR repertoire. Despite visually
443 strong correlation patterns, due to the small sample size, only anti-SARS-CoV-2 S1 and anti-RBD
444 antibody levels as detected by ELISA at pre-vaccination timepoint and at 12 weeks were
445 statistically significant after multiple testing corrections (pre-vaccination: $r_s = 0.96$, $P_{\text{adjusted}} = 0.021$;
446 12 weeks post-vaccination: $r_s = 0.98$, $P_{\text{adjusted}} = 0.003$; **Supplementary table 6**).

447 No significant differences were observed between post-vaccination increase in SARS-
448 CoV-2 specific TCR classifier scores and improvement in overall health status [spike protein
449 ($P_{\text{unadjusted}} = 0.82$), V1 ($P_{\text{unadjusted}} = 0.65$), V3 ($P_{\text{unadjusted}} = 0.56$, and non-spike ($P_{\text{unadjusted}} = 0.11$)].
450 Similarly, no differences were also observed in self-reported health status and increase in anti-
451 SARS-CoV-2 antibody levels [anti-S1 ($P_{\text{unadjusted}} = 0.73$), anti-RBD ($P_{\text{unadjusted}} = 0.48$) and anti-N
452 ($P_{\text{unadjusted}} = 0.94$)].

453

454 **Soluble immune mediators**

455 To understand the impact of vaccination on the cytokine, hormone, and proteomic profiles
456 of individuals with Long COVID, unsupervised hierarchical clustering of 162 analytes measured
457 in their plasma was first conducted (**Figure 5a**). Clustering analysis showed a consistent pattern
458 in their plasma expression profiles at 6- and 12-weeks post-vaccination. Samples clustered by
459 individual and not by timepoint post-vaccination, suggesting an entrenchment in the cytokine
460 profile of each individual that was not significantly affected by vaccination.

461 To understand the relationship of these plasma-derived analytes with post-vaccine
462 symptom outcomes, the average expression levels of each analyte was compared over all three
463 timepoints amongst three symptom outcome groups: those who did not improve or felt worse at
464 weeks 6 and 12 post vaccination ($n=3$; Same/Worse), those who showed marginal improvement
465 ($n=2$, Marginal [i.e. Better week 6; then Worse week 12]) and those who reported improvement
466 ($n=7$, Better). To do so we constructed a linear mixed model using restricted maximum likelihood
467 (REML) regression for each cytokine and accounted for both time and the interaction of time with
468 each outcome group. Thirty-five factors were found to be significant amongst these subgroups,
469 with the majority being significantly elevated in the Same/Worse group compared with the

470 improved group. Most interferon factors we measured showed some elevation amongst the
471 Same/Worse group, including IFN- β and IFN- α which were found to be significantly elevated in
472 the Same/Worse group compared to the improved group (**Figures 5b-d**). Ciliary neurotrophic
473 factor (CNTF; a neuropeptide that is released by the hypothalamus), IL-11, and SCF were also
474 significantly elevated in the Same/Worse group compared to the improved group (**Figure 5e**).
475 Other neuropeptides were noted to be elevated amongst the marginal group including oxytocin,
476 neurotensin, substance P and MSH (**Figure 5b**). Notably, soluble IL-6 receptor (sIL-6R; an anti-
477 inflammatory protein responsible for mitigating IL-6 signaling), was significantly higher amongst
478 those who showed improvement compared to the Same/Worse group (**Figure 5h**).

479 We further employed Partial Least Squares (PLS) analysis with 5-fold cross validation on
480 all 162 analytes to determine feature importance as predictors of symptom outcome and evaluate
481 concordance with the significant features obtained from our LMM models. Final analysis
482 involved reduction to 8 components, accounting for a sizeable portion of the variance in the data
483 (cumulative pseudo-R-squared= 0.99). The top two significant predictors of the PLS analysis for
484 non-improvement were IFN- β and CNTF respectively (**Figure 5i**). The top significant predictor
485 of improvement was sIL-6R (**Figure 5i**), while sgp130, an important immunological partner to
486 sIL-6R, was also associated with improvement, passing the initial VIP threshold criteria, though
487 not the additional bootstrapping threshold criteria. Taken together these results suggested that
488 high IFN and neuropeptide signaling were predictors of non-improvement while those involved
489 in mitigating cytokine signaling, namely sIL-6R, was a predictor of improvement.

490

491 **Discussion**

492 In this prospective cohort study of 16 vaccination-naïve individuals with Long COVID and
493 significant symptoms at baseline, it was observed that most people improved or stayed the same
494 during follow-up, but some experienced worsening. This study lacked concurrent controls and was
495 small, so it is challenging to make definitive statements about the effect of vaccination, particularly
496 since many people with Long COVID have fluctuations in their symptoms. However, the fact that
497 symptom burden decreased on average and more people improved than worsened suggests that the
498 vaccination was not overtly harmful. Future studies with controls are needed to understand the
499 effect of vaccination on Long COVID symptoms.

500 Our findings are consistent with other studies and systematic reviews reporting
501 improvement or non-significant change in self-reported health among people with Long COVID
502 who were vaccinated for the first time.^{18,43–45} A single-center observational study in the United
503 Kingdom identified 44 Long COVID patients (reporting a median of 4.1 and 3.6 symptoms per
504 patient) who had received at least one dose of a COVID-19 vaccine and interviewed at 1 month
505 and 8 months post-vaccination with the SF-36 and Warwick and Edinburgh Mental Wellbeing
506 scores.⁴⁶ After adjustment, health status measured with these instruments at 8 months did not differ
507 compared to Long COVID patients who were not vaccinated. In an online cross-sectional survey
508 study of 2,094 people in Switzerland, 35.5% of participants reported that their Long COVID
509 symptoms improved, 28.7% reported their symptoms were stable, and 3.3% reported their
510 symptoms worsened after vaccination.⁴⁷ In a French target trial emulation study from the
511 ComPaRe Long COVID cohort, COVID-19 vaccination was associated with a reduction in Long
512 COVID severity and symptom burden at 120 days compared with those unvaccinated.⁴⁸

513 Possible mechanisms of Long COVID have been proposed as: 1) a persistent viral reservoir
514 or “viral ghost,” which are fragments of the virus (RNA, proteins) that linger after the infection
515 has been cleared but are still capable of stimulating the immune system; 2) an autoimmune
516 response induced by the infection; 3) reactivation of latent viruses; and 4) tissue dysfunction that
517 results from inflammation triggered by the infection.^{14,20} Under these hypotheses, COVID
518 vaccination may alleviate Long COVID symptoms through vaccine-induced T cells and antibody
519 responses that may be able to eliminate the viral reservoir, and the “viral ghost,” diversion of
520 autoreactive leukocytes, or removal of inflammatory sources leading to tissue dysfunction.
521 Vaccination could also indirectly contribute to the control of latent virus reactivation by restoring
522 proper T and B cell immunity against these herpesviruses.

523 Albeit with low sample sizes, this study provides evidence for alleviation of symptoms
524 among Long COVID participants upon vaccination, along with an expected increase in SARS-
525 CoV-2 specific T-cell repertoire and anti-SARS-CoV-2 spike protein specific IgG levels.
526 However, clear results of hypothesis 1 (persistent viral reservoir) testing will be available once the
527 results of the Paxlovid trials (NCT05595369⁴⁹, NCT05668091¹⁰, NCT05823896⁵⁰,
528 NCT05576662¹¹) and monoclonal anti-spike antibody (NCT05877508) are shared with the
529 scientific community. In addition, a recent study did not find evidence of changes in circulating
530 viral proteins in response to vaccination in those with Long COVID.¹⁹

531 Our study found that the plasma-derived soluble analyte profile showed a very stable
532 pattern before and after vaccination, suggesting that vaccines had a minimal effect on the cytokine
533 dynamics of individuals at least at the time points measured. Without concurrent controls, it is
534 difficult to assess if this phenomenon is unique to individuals with Long COVID or is similar in
535 controls. Nevertheless, an overall elevated cytokine pattern—namely in interferon and
536 neuropeptide signaling—was detected among those who did not improve or showed only marginal
537 symptomatic improvement post-vaccination. These findings pose an interesting observation that
538 may help identify predictors of improvement versus non-improvement in larger studies. Elevated
539 interferon signaling suggests the possibility of an ongoing infectious viral process in these
540 individuals. The lack of improvement post-vaccination and the persistence of this signaling suggest
541 that either the vaccine was incapable of producing the necessary antibodies and T cells that clear
542 persistent infection when a viral reservoir exists, or that the main driver of disease in such
543 individuals is not SARS-CoV-2, but re-emergence of a latent infection such as EBV or
544 autoimmunity. More work will be needed to both confirm the findings of this small study and in
545 turn to decipher a possible mechanism for elevation of interferon in these individuals, including
546 the exploration of CNS involvement due to the elevation of neuropeptides which were also
547 associated with poor improvement. A recent study has shown that the persistence of IFN signaling
548 can lead to lower serotonin levels, a critical neurotransmitter⁵¹ which may also be involved in the
549 symptom profile of individuals and or these outcomes. However, given the small sample size of
550 our study, these possibilities can only be interpreted as speculative.

551 The limitations of this study include the lack of concurrent controls (i.e., individuals with
552 Long COVID who remained unvaccinated or had a sham vaccination and completed the same
553 surveys and provided biospecimens) to compare to our participants against and that most
554 participants were recruited from an online Long COVID community and had to travel to New
555 Haven, Connecticut for biospecimen collection and thus may not be representative of those with
556 Long COVID. Participants had to be physically able to travel, so they may have been less likely
557 to have severe Long COVID; at the same time, individuals more severely affected by Long COVID
558 may have been more motivated to meet the travel requirements to participate in the study, as well
559 as to be vaccinated. Participants also had to have the financial means and occupational flexibility
560 to travel. Moreover, generalizability to all individuals with Long COVID cannot be determined
561 especially for those who have developed Long COVID symptoms later in the pandemic (e.g., post-

562 Omicron era). However, this study's strengths are the prospective study design of vaccine naïve
563 individuals with Long COVID, an increasingly rare population, with assessment of symptom
564 burden, degree of physical and social disability, and immunophenotyping at multiple timepoints
565 after vaccination.

566 In conclusion, in this study of 16 individuals living with Long COVID, most people
567 improved or stayed the same, though some had worsening symptoms. Vaccination resulted in
568 increase in SARS-CoV-2 specific T-cell populations and anti-spike protein IgG levels. The top
569 predictor of participant non-improvement upon vaccination were IFN- β and CNTF, and sIL-6R
570 was found to be a predictor of improvement. Future studies are needed to better understand the
571 impact of vaccination in the health of people living with Long COVID.

572

573 **Acknowledgements**

574 We want to thank the participants who contributed to the study and patient groups for their
575 recruitment efforts and study design contributions. This work was supported in part by funds from
576 Fred Cohen and Carolyn Klebanoff and by grants from National Institute of Allergy and Infectious
577 Diseases (R01AI157488 to A.I.), the Howard Hughes Medical Institute Collaborative COVID-19
578 Initiative (to A.I.), and the Howard Hughes Medical Institute (to A.I.). J. J., T.T., and B. B. received
579 research support from Yale University from the Food and Drug Administration for the Yale-Mayo
580 Clinic Center of Excellence in Regulatory Science and Innovation (CERSI) (U01FD005938).

581

582 **References**

- 583 1. Iacobucci, G. Long covid: Damage to multiple organs presents in young, low risk patients.
584 *BMJ* m4470 (2020) doi:10.1136/bmj.m4470.
- 585 2. Huang, Y. *et al.* COVID Symptoms, Symptom Clusters, and Predictors for Becoming a
586 Long-Hauler Looking for Clarity in the Haze of the Pandemic. *Clin. Nurs. Res.* **31**, 1390–
587 1398 (2022).
- 588 3. Nehme, M. *et al.* COVID-19 Symptoms: Longitudinal Evolution and Persistence in
589 Outpatient Settings. *Ann. Intern. Med.* **174**, 723–725 (2021).
- 590 4. O'Mahoney, L. L. *et al.* The prevalence and long-term health effects of Long Covid among
591 hospitalised and non-hospitalised populations: a systematic review and meta-analysis.
592 *eClinicalMedicine* **55**, (2023).

- 593 5. Greenhalgh, T., Knight, M., A’Court, C., Buxton, M. & Husain, L. Management of post-
594 acute covid-19 in primary care. *BMJ* **370**, m3026 (2020).
- 595 6. Sudre, C. H. *et al.* Attributes and predictors of long COVID. *Nat. Med.* **27**, 626–631 (2021).
- 596 7. Davis, H. E. *et al.* Characterizing long COVID in an international cohort: 7 months of
597 symptoms and their impact. *EClinicalMedicine* **38**, 101019 (2021).
- 598 8. Lambert, N. *et al.* The other COVID-19 survivors: Timing, duration, and health impact of
599 post-acute sequelae of SARS-CoV-2 infection. *J. Clin. Nurs.* **n/a**,
- 600 9. Peluso, M. *An Exploratory, Randomized, Double-Blind Placebo-Controlled Study to Assess*
601 *the Safety of an Anti-SARS-CoV-2 Monoclonal Antibody and Response to Treatment in*
602 *Individuals With Long COVID (outSMART-LC).*
603 <https://clinicaltrials.gov/study/NCT05877508> (2023).
- 604 10. Krumholz, H. M. *An Interventional Decentralized Phase 2, Randomized, Double-Blind, 2-*
605 *Arm Study to Investigate the Efficacy and Safety of Orally Administered*
606 *Nirmatrelvir/Ritonavir Compared With Placebo/Ritonavir in Participants With Long*
607 *COVID.* <https://clinicaltrials.gov/study/NCT05668091> (2023).
- 608 11. Stanford University. *Selective Trial Of Paxlovid for PASC (STOP-PASC): Randomized*
609 *Double-Blind Placebo-Controlled Pilot Trial of Paxlovid for the Treatment of PASC.*
610 <https://clinicaltrials.gov/study/NCT05576662> (2023).
- 611 12. Yonker, L. *Phase 2a Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to*
612 *Evaluate the Safety and Efficacy of Larazotide (AT1001) for the Treatment of Long COVID*
613 *in Children and Young Adults.* <https://clinicaltrials.gov/study/NCT05747534> (2023).
- 614 13. Proal, A. D. *et al.* SARS-CoV-2 reservoir in post-acute sequelae of COVID-19 (PASC). *Nat.*
615 *Immunol.* **24**, 1616–1627 (2023).
- 616 14. Choutka, J., Jansari, V., Hornig, M. & Iwasaki, A. Unexplained post-acute infection
617 syndromes. *Nat. Med.* **28**, 911–923 (2022).
- 618 15. Davis, H. E., McCorkell, L., Vogel, J. M. & Topol, E. J. Long COVID: major findings,
619 mechanisms and recommendations. *Nat. Rev. Microbiol.* **21**, 133–146 (2023).
- 620 16. Natarajan, A. *et al.* Gastrointestinal symptoms and fecal shedding of SARS-CoV-2 RNA
621 suggest prolonged gastrointestinal infection. *Med N. Y. N* **3**, 371-387.e9 (2022).

- 622 17. Swank, Z. *et al.* Persistent Circulating Severe Acute Respiratory Syndrome Coronavirus 2
623 Spike Is Associated With Post-acute Coronavirus Disease 2019 Sequelae. *Clin. Infect. Dis.*
624 *Off. Publ. Infect. Dis. Soc. Am.* **76**, e487–e490 (2023).
- 625 18. Notarte, K. I. *et al.* Impact of COVID-19 vaccination on the risk of developing long-COVID
626 and on existing long-COVID symptoms: A systematic review. *EClinicalMedicine* **53**,
627 101624 (2022).
- 628 19. Nayyerabadi, M. *et al.* Vaccination after developing long COVID: impact on clinical
629 presentation, viral persistence and immune responses. *Int. J. Infect. Dis. IJID Off. Publ. Int.*
630 *Soc. Infect. Dis.* S1201-9712(23)00720–8 (2023) doi:10.1016/j.ijid.2023.09.006.
- 631 20. Iwasaki, A. & Putrino, D. Why we need a deeper understanding of the pathophysiology of
632 long COVID. *Lancet Infect. Dis.* **23**, 393–395 (2023).
- 633 21. Duradoni, M., Gursesli, M. C., Materassi, L., Serritella, E. & Guazzini, A. The Long-COVID
634 Experience Changed People’s Vaccine Hesitancy but Not Their Vaccination Fear. *Int. J.*
635 *Environ. Res. Public Health* **19**, 14550 (2022).
- 636 22. Massey, D. *et al.* Change in Symptoms and Immune Response in People with Post-Acute
637 Sequelae of SARS-Cov-2 Infection (PASC) After SARS-Cov-2 Vaccination.
638 2021.07.21.21260391 Preprint at <https://doi.org/10.1101/2021.07.21.21260391> (2021).
- 639 23. Iwasaki, A. How Vaccines Might Improve Long Covid. *Elemental*
640 <https://elemental.medium.com/how-vaccines-might-improve-long-covid-clf41c4d7378>
641 (2021).
- 642 24. Prof. Akiko Iwasaki [@VirusesImmunity]. This video shows that vaccines have helped some
643 people with #longCOVID with their symptoms. While the numbers are still small in some
644 groups, there are encouraging signs (also via @DanielGriffinMD). I present my hypothesis
645 on how vaccines might improve #LongCovid 📺 (1/). *Twitter*
646 <https://twitter.com/VirusesImmunity/status/1366067849480048643> (2021).
- 647 25. Vaccine Survey – Patient Led Research Collaborative.
648 <https://patientresearchcovid19.com/vaccine-survey/>.
- 649 26. Johns Hopkins COVID Long Study. *Johns Hopkins COVID Long Study* [https://covid-](https://covid-long.com/)
650 [long.com/](https://covid-long.com/).
- 651 27. Lambert, N. J., Corps, S., El-Azab, S., Yu, L. & Esperanca, A. Fever Scans Offer False
652 Sense of Security for Stopping the Spread of COVID-19. (2020).

- 653 28. Lambert, N. J. & Corps, S. COVID-19 “Long Hauler” Symptoms Survey Report. (2020).
- 654 29. Assaf, G. *et al.* Report: What Does COVID-19 Recovery Actually Look Like? – Patient Led
655 Research Collaborative. <https://patientresearchcovid19.com/research/report-1/>.
- 656 30. Klein, J. *et al.* Distinguishing features of Long COVID identified through immune profiling.
657 *MedRxiv Prepr. Serv. Health Sci.* 2022.08.09.22278592 (2022)
658 doi:10.1101/2022.08.09.22278592.
- 659 31. Snyder, T. M. *et al.* Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2
660 Infection at Both Individual and Population Levels. *MedRxiv Prepr. Serv. Health Sci.*
661 2020.07.31.20165647 (2020) doi:10.1101/2020.07.31.20165647.
- 662 32. Adaptive Biotechnologies Corporation. Emergency Use Authorization (EUA) Summary T-
663 Detect COVID Test. (2021).
- 664 33. Klinger, M. *et al.* Multiplex Identification of Antigen-Specific T Cell Receptors Using a
665 Combination of Immune Assays and Immune Receptor Sequencing. *PLoS One* **10**, e0141561
666 (2015).
- 667 34. Leek, J. T., Johnson, W. E., Parker, H. S., Jaffe, A. E. & Storey, J. D. The sva package for
668 removing batch effects and other unwanted variation in high-throughput experiments.
669 *Bioinformatics* **28**, 882–883 (2012).
- 670 35. R Core Team. R: A language and environment for statistical computing.
- 671 36. Morpheus. <https://software.broadinstitute.org/morpheus/>.
- 672 37. Wold, S., Johansson, E. & Cocchi, M. PLS: Partial Least Squares Projections to Latent
673 Structures. in (1993).
- 674 38. Kubinyi, H. 3D QSAR in drug design : theory, methods and applications. in (2000).
- 675 39. Su, Y. *et al.* Multiple early factors anticipate post-acute COVID-19 sequelae. *Cell* **185**, 881-
676 895.e20 (2022).
- 677 40. Gold, J. E., Okyay, R. A., Licht, W. E. & Hurley, D. J. Investigation of Long COVID
678 Prevalence and Its Relationship to Epstein-Barr Virus Reactivation. *Pathog. Basel Switz.* **10**,
679 763 (2021).
- 680 41. Wang, E. Y. *et al.* Diverse functional autoantibodies in patients with COVID-19. *Nature* **595**,
681 283–288 (2021).
- 682 42. Jaycox, J. R. *et al.* SARS-CoV-2 mRNA vaccines decouple anti-viral immunity from
683 humoral autoimmunity. *Nat. Commun.* **14**, 1299 (2023).

- 684 43. Tsuchida, T. *et al.* Relationship between changes in symptoms and antibody titers after a
685 single vaccination in patients with Long COVID. *J. Med. Virol.* **94**, 3416–3420 (2022).
- 686 44. Watanabe, A., Iwagami, M., Yasuhara, J., Takagi, H. & Kuno, T. Protective effect of
687 COVID-19 vaccination against long COVID syndrome: A systematic review and meta-
688 analysis. *Vaccine* **41**, 1783–1790 (2023).
- 689 45. Byambasuren, O., Stehlik, P., Clark, J., Alcorn, K. & Glasziou, P. Effect of covid-19
690 vaccination on long covid: systematic review. *BMJ Med.* **2**, e000385 (2023).
- 691 46. Arnold, D. T. *et al.* Are vaccines safe in patients with Long COVID? A prospective
692 observational study. 2021.03.11.21253225 Preprint at
693 <https://doi.org/10.1101/2021.03.11.21253225> (2021).
- 694 47. Nehme, M. *et al.* Symptoms After COVID-19 Vaccination in Patients with Post-Acute
695 Sequelae of SARS-CoV-2. *J. Gen. Intern. Med.* **37**, 1585–1588 (2022).
- 696 48. Tran, V.-T., Perrodeau, E., Saldanha, J., Pane, I. & Ravaud, P. Efficacy of first dose of
697 covid-19 vaccine versus no vaccination on symptoms of **patients** with long covid: target trial
698 emulation based on ComPaRe e-cohort. *BMJ Med.* **2**, e000229 (2023).
- 699 49. Zimmerman, K. O. *RECOVER-VITAL: A Platform Protocol for Evaluation of Interventions*
700 *for Viral Persistence, Viral Reactivation, and Immune Dysregulation in Post-Acute Sequelae*
701 *of SARS-CoV-2 Infection (PASC)*. <https://clinicaltrials.gov/study/NCT05595369> (2023).
- 702 50. Brodin, P. *An Interventional, Double-Blinded, 2-Arm Study to Investigate the Efficacy of*
703 *Orally Administered Nirmatrelvir/Ritonavir Compared With Placebo/Ritonavir in Non-*
704 *hospitalized Adult Participants Suffering From Post-COVID.*
705 <https://clinicaltrials.gov/study/NCT05823896> (2023).
- 706 51. Wong, A. C. *et al.* Serotonin reduction in post-acute sequelae of viral infection. *Cell* **186**,
707 4851-4867.e20 (2023).
- 708

709 **Table and Figures**

710

Characteristic	n=16 (%)
Age, Median (Min-Max)	54 (21-69)
Missing	1
Gender	
Female	13 (81%)
Male	3 (19%)
Race/ethnicity	
American Indian/Alaska Native	1 (6%)
Hispanic	1 (6%)
Non-Hispanic White	14 (88%)
Tested for COVID-19	16 (100%)
Hospitalized due to COVID-19	3 (19%)
Hospitalized for COVID-19 or visited a hospital more than 2 weeks after infection	4 (25%)
Test type	
Antigen test	2 (12%)
Not sure	4 (25%)
PCR test	10 (62%)
On your best days would you say you are ___ of health before COVID-19	
0-25% of health before COVID-19	0
26-50% of health before COVID-19	1 (6%)
51-75% of health before COVID-19	7 (44%)
76-100% of health before COVID-19	8 (50%)
On your worst days would you say you are ___ of health before COVID-19	
0-25% of health before COVID-19	5 (31%)
26-50% of health before COVID-19	4 (25%)
51-75% of health before COVID-19	6 (38%)
76-100% of health before COVID-19	1 (6%)

711

712 **Table 1: Baseline characteristics**


713

714

715

716


717



718
719
720
721
722
723
724
725

Figure 1: Trends of the ten most common symptoms before vaccination.


The proportion of symptoms experienced was calculated at each survey as the number of participants experiencing each symptom (i.e., symptom reported and non-zero response to the physical or social effect scales) out of the participants who completed the given survey. Data missing for n=2 at 2 weeks and n=2 at 6 weeks.



726
727
728
729
730
731
732
733

Figure 2: Overall health change since receiving first dose of COVID-19 vaccine, measured with surveys sent 2, 6, and 12 weeks after vaccination.


Participants were asked “Would you say that your overall health, as compared to your health before the vaccine, is worse, better, or the same?” at each post-vaccination survey. Data missing for n=2 at 2 weeks and n=2 at 6 weeks.



734
735


736 **Figure 3: Distribution of the sum of participants' responses to two measures of symptom**
737 **severity—physical and social effects—measured before vaccination and surveys sent 2, 6,**
738 **and 12 weeks after vaccination.**

739 To measure physical effect of each symptom from a list of 125 symptoms, participants were asked,
740 “While experiencing these symptoms, how much do/did they bother you in terms of discomfort or
741 pain?” Similarly, to measure social effects, participants were asked, “After quarantine, how much
742 does/did the symptom impair your social or family functioning compared to pre-COVID?
743 Responses for each symptom were scored 0 to 4 (Supplementary table 1) and summed for each
744 participant. Boxplots show the distribution of responses, with points representing the score for
745 each participant and lines showing participants' trajectory across surveys. Data missing for n=2 at
746 2 weeks and n=2 at 6 weeks.



747
 748 **Figure 4: Vaccination resulted in increase in SARS-CoV-2 T-cell repertoires and specific**
 749 **humoral responses among Long COVID participants.**


750 (a) Model scores and binary classifications are plotted against days post-vaccination using spike
751 viral protein specific classifier (b) COVID classifier version 1 (v1) (c) COVID classifier version
752 3 (v3) (d) Non-spike-specific protein classifier (e) Line plots of matched anti-SARS-CoV-2 S1
753 IgG concentrations before, 6 and 12 weeks post-vaccination in Long COVID participants. (f) Line
754 plots of matched anti-SARS-CoV-2 RBD IgG concentrations before, 6 and 12 weeks post-
755 vaccination in Long COVID participants. (g) Line plots of matched anti-SARS-CoV-2 N IgG
756 concentrations before, 6 and 12 weeks post-vaccination in Long COVID participants. The color
757 codes denote the reported health status at 6 and 12 weeks post-vaccination, better at both
758 timepoints [teal], no change at both timepoints [blue], better at 6 weeks and worse at 12 weeks
759 [purple] & worse at both timepoints [orange]. (h) Line plots of matched anti-SARS-CoV-2 Epsilon
760 variant reactivity scores against the Spike protein assessed by Rapid Extracellular Antigen
761 Profiling (REAP) (i) Heatmap of REAP reactivities against 10 viral proteins namely, proteins
762 belonging to common viral pathogens from *Coronaviridae* (human SARS-CoV-1 viruses),
763 *Herpesviridae* families, and the Rubella vaccine protein. Each protein and each participant
764 timepoint are represented as a row and a column respectively. The participant IDs are mentioned
765 below each column and the numbers after decimal denote the collection timepoints after
766 vaccination (6 weeks= 2; 12 weeks= 3). Statistical significance determined by Wilcoxon Rank
767 tests and corrected for multiple testing using the Bonferroni method. (j) EBV p23 REAP scores
768 among outcome groups. Significance was assessed using Kruskal–Wallis tests. (k) EBV gp42
769 REAP scores among outcome groups. (l) Hierarchical clustering of Spearman Rank correlation
770 coefficients of TCR model scores, antibody concentrations and REAP scores at all three
771 timepoints. Only adjusted p-values of <0.05 are mentioned in line plots and denoted by asterisks
772 in heatmaps.



774 **Figure 5: Elevated interferon and neuropeptide signaling is associated with poor recovery**
775 **post-vaccination.**


776 (a) Unsupervised hierarchical clustering of plasma-derived analyte expression within the cohort
777 for all three sample timepoints (pre-vaccination, 6 weeks post series completion, and 12 weeks
778 post series completion). Color panel above heatmap shows the symptom outcome subgroup of
779 each individual as indicated by the key. Samples for each individual are labeled by their sample
780 code LC.R.HK.1.00XX.tX, where XX designates the patient ID and tX designates the timepoint
781 (t1= pre vaccination, t2= 6 weeks post series completion, and t3= 12 weeks post series completion).
782 Sample label color indicates further categorization into Same/Worse (orange), marginal
783 improvement (i.e., better than worse; purple), and Improved (teal). Color scale is magma and is
784 normalized for each analyte (data table columns) with darker colors indicating higher relative
785 expression and lighter colors indicating lower expression as shown by the key. (b) Expression
786 Heatmap of significant differentially expressed factors between symptom outcome groups
787 (Same/Worse, Marginal, and Improved), as labeled. Each subgroup is further separated by the
788 vaccine timepoint. Each factor was centered and standardized to generate a z-score and colors are
789 representative of expression as indicated by the legend. To show significance between groups,
790 samples were organized with outer brackets of the heatmap indicating the symptom outcome group
791 demonstrating significantly lower expression and inner brackets indicating the comparator group
792 from which significance is derived. Significance was determined using linear mixed models
793 (LMM) via restricted maximum likelihood (REML) regression for log-transformed values,
794 accounting for repeated measures across individuals over time as described in the methods and
795 adjusted for multiple comparisons within each parameter using the Tukey method. (c-h) Example
796 differentially expressed factors between symptom outcome groups as determined by LMM,
797 previously described. (i) Top 20 bootstrapped predictors of symptom outcome (unimproved vs
798 improved), determined by Partial Least Squares (PLS) optimized at eight components. Predictors
799 are ordered by importance with highest importance on the left. Color and direction of each bar
800 represents the relative regression association to unimproved individuals with positive values
801 showing a positive association and negative values showing a negative association. Color is
802 determined by regression as shown. Details of NIPALS and detailed results can be found in the
803 methods and in extended data, respectively.

804
805
806
807
808
809
810
811



812 **Supplementary Figure 1: Increased reactivity in non-Omicron specific RBD epitopes post-**
813 **vaccination.**

814 (a) Line plots of matched anti-SARS-CoV-2 Beta variant reactivity scores against the Spike protein
815 assessed by Rapid Extracellular Antigen Profiling (REAP) (b) Anti-SARS-CoV-2 Delta variant
816 reactivity scores (c) Anti-SARS-CoV-2 Omicron variant reactivity scores. Statistical significance
817 was determined by Wilcoxon with Bonferroni correction for multiple comparisons. Only
818 significant values are mentioned in the graphs.
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843



844
 845 **Supplementary Figure 2:** (a) REAP reactivities across the cohort at the first time point. Each
 846 column is one participant, grouped by cohort (B/W = marginal). Each row represents one protein.
 847 Reactivities shown have at least one participant with a REAP score ≥ 1 . (b) The number of
 848 autoantibody (aAb) reactivities per individual (ID) by group. Significance was assessed using
 849 Kruskal-Wallis tests. (c) Average REAP score delta for autoantibody reactivities per individual
 850 from the first to the final time point. Significance was assessed using Kruskal-Wallis tests. For
 851 the box plots, the central lines indicate the group median values, the top and bottom lines indicate
 852 the 75th and 25th percentiles, respectively, the whiskers represent $1.5 \times$ the interquartile range.

853 Each dot represents one individual. (d) Autoantibody trajectory for one individual during
 854 vaccination. Each line represents one reactivity (red = SARS-CoV2, blue = Herpesvirus, black =
 855 autoantibody. (e) overlay plot of all anti-viral and autoantibodies detected normalized to a starting
 856 REAP score of 0. Each line represents one reactivity.
 857
 858

Measure of symptom severity	Survey questions	Likert scale response
Physical	“While experiencing these symptoms, how much do/did they bother you in terms of discomfort or pain?”	Not at all = 0 A little bit = 1
Social	“After quarantine, how much does/did the symptom impair your social or family functioning compared to pre-COVID?”	Somewhat = 2 Quite a bit = 3 Very much = 4

859 **Supplementary Table 1:** Survey questions assessing the physical and social effects for each
 860 symptom prior to vaccination and at surveys sent 2, 6, and 12 weeks after vaccination.
 861
 862

Pre-vaccine (n=16)	2 weeks (n=14)	6 weeks (n=14)	12 weeks (n=16)
Brain fog (81%)	Fatigue (86%)	Fatigue (86%)	Fatigue (75%)
Fatigue (75%)	Brain fog (79%)	Brain fog (79%)	Brain fog (69%)
Difficulty concentrating or focusing (69%)	Difficulty concentrating or focusing (71%)	Difficulty concentrating or focusing (71%)	Heart palpitations (56%)
Difficulty sleeping (62%)	Anxiety (64%)	Anxiety (57%)	Anxiety (50%)
Heart palpitations (56%)	Heart palpitations (57%)	Heart palpitations (57%)	Difficulty concentrating or focusing (50%)
Shortness of breath or difficulty breathing (56%)	Shortness of breath or difficulty breathing (57%)	Headache (50%)	Difficulty sleeping (50%)
Anxiety (50%)	Feeling irritable (50%)	Shortness of breath or difficulty breathing (50%)	Post-exertional malaise (50%)
Memory problems (50%)	Memory problems (50%)	Diarrhea (43%)	Headache (44%)
Dizziness (44%)	Post-exertional malaise (50%)	Difficulty sleeping (43%)	Inability to exercise or be active (44%)
Feeling irritable (44%)	Difficulty sleeping (43%)	Inability to exercise or be active (43%)	Shortness of breath or difficulty breathing (44%)

863 **Supplementary Table 2:** Ten most common symptoms prior to vaccination and at surveys sent 2,
 864 6, and 12 weeks after vaccination. Data missing for n=2 at 2 weeks and n=2 at 6 weeks.
 865

866 **Supplementary File:** Blank study surveys sent to participants prior to vaccination and 2, 6, and
 867 12 weeks after vaccination (PDF) and Supplementary tables 3-6 (Excel file).